A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

July 7, 2021

Study Completion Date

August 19, 2021

Conditions
Epicondylitis
Interventions
DRUG

Injection, botulinum toxin + corticoid

"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"

DRUG

Injection, placebo of toxin + corticoid

"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"

DRUG

Injection, botulinum toxin + placebo corticoid

"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"

Trial Locations (1)

92380

Service de Médecine Physique et de Réadaptation, Hôpital Raymond Poincaré, Garches

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03380559 - A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis | Biotech Hunter | Biotech Hunter